Use of granulocyte colony-stimulating factor in the treatment of acute infectious diseases

Current Opinion in Hematology

Volumn 4, Issue 3, 1997, Pages 207-212

  Stoltz, David A ^a   Bagby, Gregory J ^a   Nelson, Steve ^a  

^a LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR;

ADJUVANT THERAPY; CLINICAL TRIAL; HUMAN; IMMUNE SYSTEM; INFECTION; MORBIDITY; MORTALITY; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; REVIEW; UNITED STATES;

EID: 0030767894     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199704030-00009     Document Type: Review

References (31)

1. Fleming A: On the antibacterial action of cultures of a Penicillium, with special reference to their use in the Isolation of B. influenzae. Br J Exp Pathol 1929, 10:226-236.
2. Abraham EP, Chain E: An enzyme from bacteria able to destroy penicillin. Nature 1940, 146:837.
3. Pinner RW, Teutsch SM, Simonsen L, Klug LA, Graber JM, Clarke MJ, Berkelman RL: Trends in infectious diseases mortality in the United States. JAMA 1996, 275:189-193.
4. Bradley TR, Metcalf D: The growth of mouse bone marrow cells in vitro. Aust J Exp Biol Med Sci 1966, 44:287-300.
5. Nicola NA, Metcalf D, Matsumoto M, Johnson GR: Purification of a factor inducing differentiation in murine myelomonocytic leukemia cells. J Biol Chem 1983, 258:9017-9023.
6. Lieschke GJ, Grail D, Hodgson G, Metcalf D, Stanley E, Cheers C, Fowler KJ, Basu S, Zhan YF, Dunn AR: Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood 1994, 84:1737-1746.
7. Waring PM, Presneill J, Maher DW, Layton JE, Cebon J, Waring LJ, Metcalf D: Differential alterations in plasma colony-stimulating factor concentrations in meningococcaemia. Clin Exp Immunol 1995, 102:501-506.
8. Kragsbjerg P, Jones I, Vikerfors T, Holmberg H: Diagnostic value of blood cytokine concentrations in acute pneumonia. Thorax 1995, 50:1253-1257.
9. Tanaka H, Ishikawa K, Nishino M, Shimazu T, Yoshioka T: Changes in granulocyte colony-stimulating factor concentration in patients with trauma and sepsis. J Trauma 1996, 40:718-726.
10. Dale DC, Liles WC, Summer WR, Nelson S: Review:granulocyte colony stimulating factor-role and relationships in infectious diseases. J Infect Dis 1995, 172:1061-1075. A review article detailing the discovery, physiologic effects, and uses of G-CSF in the setting of infectious diseases.
11. Lloyd AR, Biragyn A, Johnston JA, Taub DD, Xu L, Michiel D, Sprenger H, Oppenheim JJ, Kelvin DJ: Granulocyte colony-stimulating factor and lipopolysaccharide regulate the expression of interleukin B receptors on polymorphonuclear leukocytes. J Biol Chem 1995, 270:28188-28192. Describes G-CSF's upregulation of IL-8 receptor mRNA expression in PMNs. This paper provides a potential mechanism for the increased neutrophil influx into sites of infection observed during G-CSF therapy.
12. Nelson S, Summer W, Bagby G, Nakamura C, Stewart L, Lipscomb G, Andresen J: Granulocyte colony-stimulating factor enhances pulmonary host defenses in normal and ethanol-treated rats. J Infect Dis 1991, 164:901-906.
13. Al-Shammary FJ, Al-Zamel F, El-Shewemi S, Soliman R: Effect of rh-GMCSF and rh-GCSF on oxygen free radical production by human neutrophils and blood monocyte-derived human macrophages. Renal Physiol Biochem 1995, 18:278-287.
14. Daschner FD, Grundmann H, Anding K, Lemmen S: Combined effect of human neutrophils, ceftazidime and granulocyte colony-stimulating factor on killing of Escherichia coli. Eur J Clin Microbiol Infect Dis 1995, 14:536-539.
15. Kropec A, Lemmen SW, Grundmann HJ, Engels I, Daschner FD: Synergy of simultaneous administration of ofloxacin and granulocyte colony-stimulating factor in killing of Escherichia coli by human neutrophils. Infection 1995, 23:298-300.
16. McKenna PJ, Nelson S, Andresen J: Filgrastim (rhuG-CSF) enhances ciprofloxacin uptake and bactericidal activity of human neutrophils in vitro [abstract]. Am J Respir Crit Care Med 1996, 153:A535. The authors report that G-CSF acts synergistically with ciprofloxacin in enhancing PMN bactericidal activity, by promoting PMN uptake of ciprofloxacin. A possible consequence of this phenomenon is enhanced transport of antibiotics to infectious sites by PMNs.
17. Mooney DP, Gamelli RL, O'Reilly M, Hebert JC: Recombinant human granulocyte colony-stimulating factor and Pseudomonas burn wound sepsis. Arch Surg 1988, 123:1353-1357.
18. Dunne JR, Dunkin BJ, Nelson S, White JC: Effects of granulocyte colony stimulating factor in a nonneutropenic rodent model of Escherichia coli peritonitis. J Surg Res 1996, 61:348-354. With a peritonitis model, G-CSF treatment is shown to reduce peritonitis-induced mortality and improve bactericidal activity of PMNs recovered by peritoneal lavage.
19. Lundblad R, Nesland JM, Giercksky K: Granulocyte colony-stimulating factor improves survival rate and reduces concentrations of bacteria, endotoxin, tumor necrosis factor, and endothelin-1 in fulminant intra-abdominal sepsis in rats. Crit Care Med 1996, 24:820-826. A model of peritonitis that reports enhanced survival in G-CSF-treated animals. In addition, G-CSF-treated septic animals had a decrease in plasma levels of bacteria, tumor necrosis factor, and endothelin-1. There were no adverse effects due to G-CSF therapy.
20. Preheim LC, Snitily MU, Gentry MJ: Effects of granulocyte colony-stimulating factor in cirrhotic rats with pneumococcal pneumonia. J Infect Dis 1996, 174:225-228.
21. Terashima T, Kanazawa M, Sayama K, Urano T, Sakamaki F, Nakamura H, Waki Y, Soejima K, Tasaka S, Ishizaka A: Neutrophil-induced lung protection and injury are dependent on the amount of Pseudomonas aeruginosa administered via airways in guinea pigs. Am J Respir Crit Care Med 1995, 152:2150-2156.
22. Rao R, Prinz RA, Kazantsev GB, Hecht D, Gattuso P, Jacobs HK, Djuricin G, Castelli M: Effects of granulocyte colony-stimulating factor in severe pancreatitis. Surgery 1996, 119:657-663
23. Vignes S, Fantin B, Elbim C, Walker F, Gougerot-Pocidalo M, Carbon C: Critical influence of timing of administration of granulocyte colony-stimulating factor on antibacterial effect in experimental endocarditis due to Pseudomonas aeruginosa. Antimicrob Agents Chemother 1995, 39:2702-2707.
24. Zhang P, Bagby GJ, Stoltz DA, Spitzer JA, Summer WR, Nelson S: Modulation of the lung host response by granulocyte colony-stimulating factor in rats challenged with intrapulmonary endotoxin. Shock 1997, 7:193-199.
25. Price TH, Chatta GS, Dale DC: Effect of recombinant granulocyte colony-stimulating factor on neutrophil kinetics in normal young and elderly humans. Blood 1996, 88:335-340. An important study designed to further characterize PMN kinetics following G-CSF treatment and to examine the safety and efficacy of G-CSF therapy in the elderly. Administration of G-CSF to elderly subjects resulted in the same effects on PMN kinetics as in young subjects (neutrophilia, an increase in marrow neutrophil mitotic pool size, and a decrease in marrow neutrophil postmitotic pool size). In addition, no deleterious effects due to G-CSF treatment were observed in either group.
26. Sato E, Yamamoto H, Honda T, Koyama S, Kubo K, Sediguchi M: Acute respiratory distress syndrome due to methicillin-resistant Staphylococcus aureus sepsis in hyper-IgE syndrome. Bur Respir J 1996, 9:386-388.
27. Rosenthal J, Healey T, Ellis R, Gillan E, Cairo MS: A two-year follow-up of neonates with presumed sepsis treated with recombinant human granulocyte colony-stimulating factor during the first week of life. J Pediatr 1996, 128:135-137.
28. Gillan ER, Christensen RD, Suen Y, Ellis R, van de Ven C, Cairo MS: A randomized, placebo-controlled trial of recombinant human granulocyte colony-stimulating factor administration in newborn infants with presumed sepsis: significant induction of peripheral and bone marrow neutrophilia. Blood 1994, 84:1427-1433.
29. Nishida T, Hasegawa J, Nakao K, Fujita N: Granulocyte colony-stimulating factor for gastrointestinal perforation in patients with leukopenia. J Trauma 1996, 40:727-732.
30. Wunderink RG, Leeper KV, Schein RMH, Nelson S, DeBoisblanc B, Baker F, Fotheringham N, Logan E: Clinical response to filgrastim (r-metHuG-CSF) in pneumonia with severe sepsis [abstract]. Am J Respir Crit Care Med 1996, 153:A123. A phase I/II trial of patients with pneumonia and septic shock reporting that G-CSF treatment decreases mortality and enhances resolution of end-organ failure when compared with the placebo group. An important study that did not show any adverse effects of G-CSF therapy in these critically ill patients and provides evidence to support G-CSF treatment of serious infections.
31. Nelson S, Farkas S, Fotheringham N, Ho H, Marrie T, Movahhed H: Filgrastim in the treatment of hospitalized patients with community acquired pneumonia (CAP) [abstract]. Am J Respir Crit Care Med 1996, 153:A535. A report of a phase III trial of 756 hospitalized patients with community-acquired pneumonia designed to examine the safety and effectiveness of G-CSF treatment. Chest radiograph resolution was hastened in G-CSF-treated patients, and a decrease in complications from the initial infectious event was observed. Significantly, no adverse effects due to G-CSF therapy were noted.